Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/10217| Title: | Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+advanced breast cancer: BOLERO-1 |
| Authors: | HURVITZ, Sara A.; ANDRE, Fabrice; JIANG, Zefei; SHAO, Zhimin; NECIOSUP, Silvia P.; MANO, Max S.; TSENG, Ling-Min; ZHANG, Qingyuan; SHEN, Kunwei; LIU, Donggeng; DREOSTI, Lydia M.; FENG, Jifeng; BURRIS, Howard A.; TOI, Masakazu; BUYSE, Marc E.; CABARIBERE, David; LINDSAY, Mary-Ann; KUNZ, Tiffany; RAO, Shantha; PACAUD, Lida B.; TARAN, Tetiana; SLAMON, Dennis |
| Citation: | CANCER RESEARCH, v.75, n.9, suppl.S, 2015 |
| Appears in Collections: | Comunicações em Eventos - FM/MDR Comunicações em Eventos - LIM/24 |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.